IMTO-4842.1

IMTO-4842.1 (also known as IMTO-4842) is a preclinical-stage, mutation-agnostic antibody-drug conjugate (ADC) being developed by Immuto Scientific for the treatment of acute myeloid leukemia (AML). Discovered using Immuto's AI-enabled structural surfaceomics platform, the therapeutic targets a conformationally distinct, disease-specific surface protein conformer (SPC) found on AML cells. By selectively binding to this unique structural variant rather than the wild-type protein found on healthy tissues, IMTO-4842.1 is designed to deliver its cytotoxic payload directly to leukemia cells while minimizing off-target toxicities, such as those affecting healthy hematopoietic stem cells. The program is in CMC and preclinical development, with preclinical data scheduled for presentation at the ASH 2026 Annual Meeting.